Effect of the α2C-adrenoreceptor deletion322-325 variant on sympathetic activity and cardiovascular measures in healthy subjects

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 763-771

  Kurnik, Daniel ^a   Muszkat, Mordechai ^a   Friedman, Eitan A ^a   Sofowora, Gbenga G ^a   Diedrich, André ^a   Xie, Hong Guang ^a   Harris, Paul A ^a   Choi, Leena ^a   Wood, Alastair J J ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 2 adrenergic receptors; Blood pressure; Catecholamines; Genetic polymorphism; Sympathetic nervous system

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DIASTOLIC BLOOD PRESSURE; ETHNICITY; FEMALE; GENE DELETION; GENOTYPE; HEART RATE; HEART RATE VARIABILITY; HUMAN; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PRIORITY JOURNAL; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; ADRENERGIC SYSTEM; AFRICAN AMERICAN; BLOOD; CAUCASIAN; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; METHODOLOGY; PHENOTYPE; PHYSIOLOGY; REFERENCE VALUE; REST; UNITED STATES;

ADULT; AFRICAN AMERICANS; BIOLOGICAL MARKERS; BLOOD PRESSURE; EPINEPHRINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; HEART RATE; HUMANS; MALE; NOREPINEPHRINE; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-2; REFERENCE VALUES; RESEARCH DESIGN; REST; SYMPATHETIC NERVOUS SYSTEM; TENNESSEE;

EID: 33947096021     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328017f6e9     Document Type: Article

References (49)

1. Robertson D, Biaggioni I, Burnstock G, Low PA. Primer on the autonomic nervous system. San Diego, CA: Elsevier Academic Press; 2004.
2. Dao TT, Kailasam MT, Parmer RJ, Le HV, Le Verge R, Kennedy BP, et al. Expression of altered alpha2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension. J Hypertens 1998; 16:779-792.
3. Ferrier C, Cox H, Esler M. Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci (Lond) 1993; 84:225-230.
4. Williams PD, Puddey IB, Beilin LJ, Vandongen R. Genetic influences on plasma catecholamines in human twins. J Clin Endocrinol Metab 1993; 77:794-799.
5. Kennedy BP, Rao F, Botiglieri T, Sharma S, Lillie EO, Ziegler MG, et al. Contributions of the sympathetic nervous system, glutathione, body mass and gender to blood pressure increase with normal aging: influence of heredity. J Hum Hypertens 2005; 19:951-969.
6. Flordellis C, Manolis A, Scheinin M, Paris H. Clinical and pharmacological significance of alpha2-adrenoceptor polymorphisms in cardiovascular diseases. Int J Cardiol 2004; 97:367-372.
7. Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 2004; 56:31-52.
8. O'Connor DT, Insel PA, Ziegler MG, Hook VY, Smith DW, Hamilton BA, et al. Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep 2000; 2:16-22.
9. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402:181-184.
10. Bucheler MM, Hadamek K, Hein L. Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 2002; 109:819-826.
11. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002; 106:2491-2496.
12. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol 2003; 17:1640-1646.
13. Chotani MA, Mitra S, Su BY, Flavahan S, Eid AH, Clark KR, et al. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004; 286:H59-H67.
14. Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, Liggett SB. Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci U S A 2004; 101:13020-13025.
15. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275:23059-23064.
16. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-1142.
17. Neumeister A, Charney DS, Belfer I, Geraci M, Holmes C, Sharabi Y, et al. Sympathoneural and adrenomedullary functional effects of alpha2Cadrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 2005; 15:143-149.
18. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:e85-e151.
19. Li JL, Canham RM, Vongpatanasin W, Leonard D, Auchus RJ, Victor RG. Do allelic variants in α2A and α2C adrenergic receptors predispose to hypertension in blacks? Hypertension 2006; 47:1140-1146.
20. Wang X, Thayer JF, Treiber F, Snieder H. Ethnic differences and heritability of heart rate variability in African- and European American youth. Am J Cardiol 2005; 96:1166-1172.
21. Muszkat M, Kurnik D, Solus J, Sofowora GG, Xie HG, Jiang L, et al. Variation in the alpha2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genomics 2005; 15:407-414.
22. Kurnik D, Muszkat M, Li C, Sofowora GG, Solus J, Xie HG, et al. Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther 2006; 79:173-185.
23. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-161.
24. Belfer I, Buzas B, Hipp H, Phillips G, Taubman J, Lorincz I, et al. Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene. J Hum Genet 2005; 50:12-20.
25. He HB, Deegan RJ, Wood M, Wood AJ. Optimization of high-performance liquid chromatographic assay for catecholamines. Determination of optimal mobile phase composition and elimination of species-dependent differences in extraction recovery of 3,4-dihydroxybenzylamine. J Chromatogr 1992; 574:213-218.
26. Pan J, Tompkins WJ. A real-time QRS detection algorithm. IEEE Trans Biomed Eng 1985; 32:230-236.
27. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93:1043-1065.
28. Oppenheim A, Schafer R. Digital signal processing. Englewood Cliffs, NJ: Prentice Hall; 1975.
29. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76:887-893.
30. Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, et al. Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. Eur J Heart Fail 2006; 8:131-135.
31. Nonen S, Okamoto H, Akino M, Matsui Y, Fujio Y, Yoshiyama M, et al. No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol 2005; 60:414-417.
32. Ruppert M, Overlack A, Kolloch R, Kraft K, Gobel B, Stumpe KO. Neurohormonal and metabolic effects of severe and moderate salt restriction in non-obese normotensive adults. J Hypertens 1993; 11:743-749.
33. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 1996; 273:803-805.
34. Powis DA, Baker PF. Alpha 2-adrenoceptors do not regulate catecholamine secretion by bovine adrenal medullary cells: a study with clonidine. Mol Pharmacol 1986; 29:134-141.
35. Berkowitz DE, Price DT, Bello EA, Page SO, Schwinn DA. Localization of messenger RNA for three distinct alpha 2-adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology 1994; 81:1235-1244.
36. Parmer RJ, Cervenka JH, Stone RA. Baroreflex sensitivity and heredity in essential hypertension. Circulation 1992; 85:497-503.
37. Lillie EO, O'Connor DT. Early phenotypic changes in hypertension: a role for the autonomic nervous system and heredity. Hypertension 2006; 47:331-333.
38. Kim JR, Kiefe CI, Liu K, Williams OD. Jacobs DR Jr, Oberman A. Heart rate and subsequent blood pressure in young adults: the CARDIA study. Hypertension 1999; 33:640-646.
39. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119:133-141.
40. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358:1682- 1686.
41. Greenlund KJ, Kiefe CI, Gidding SS, Lewis CE, Srinivasan SR, Williams OD, et al. Differences in cardiovascular disease risk factors in black and white young adults: comparisons among five communities of the CARDIA and the Bogalusa heart studies. Coronary Artery Risk Development In Young Adults. Ann Epidemiol 1998; 8:22-30.
42. Paul TK, Srinivasan SR, Wei C, Li S, Bhuiyan AR, Bond MG, et al. Cardiovascular risk profile of asymptomatic healthy young adults with increased femoral artery intima-media thickness: The Bogalusa Heart Study. Am J Med Sci 2005; 330:105-110.
43. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, et al. Heart rate as marker of sympathetic activity. J Hypertens 1998; 16:1635-1639.
44. Rea RF, Eckberg DL, Fritsch JM, Goldstein DS. Relation of plasma norepinephrine and sympathetic traffic during hypotension in humans. Am J Physiol 1990; 258:R982-R986.
45. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558-562.
46. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474-80.
47. Peng YX, Shan J, Qi XY, Zhang SJ, Ma SP, Wang N, et al. The catecholamine-beta-adrenoreceptor-cAMP system and prediction of cardiovascular events in hypertension. Clin Exp Pharmacol Physiol 2006; 33:227-231.
48. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
49. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94:690-697.